-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*It is only for medical professionals to read for reference.
Maybe we can't fight the wrinkles that the years bring to our mothers, but for their health, we must work hard to spare! Today is Mother's Day.
While thanking mothers for their nurturing, we should pay more attention to the health of mothers.
As we grow up, our parents are getting older.
After they enter the old age, the risk of various chronic diseases gradually increases, and there is no lack of elderly diabetes, which has a significantly higher prevalence in my country.
Diabetes patients aged ≥65 years are defined as elderly diabetic patients, including elderly people diagnosed with diabetes before and after 65 years of age, and about half of them are female patients.
Data in 2019 shows that the number of elderly diabetic patients ≥ 65 years old in China is about 35.
5 million, ranking first in the world, accounting for a quarter of the global elderly diabetic patients, and showing an upward trend.
Clinically, elderly diabetic patients have their own characteristics, so how to carry out standardized management? On January 27, 2021, the "Guidelines for Diagnosis and Treatment of Diabetes in the Aged in China (2021 Edition)" (hereinafter referred to as "Guidelines") jointly organized and compiled by the National Geriatrics Center, Chinese Medical Association Branch of Geriatrics and China Geriatric Health Care Association (hereinafter referred to as "Guidelines") will be held in Beijing.
Convened.
What are the renewal of concepts brought about by the "Guide" in the management of elderly diabetes, and what recommendations have been made for clinical practice? To this end, Professor Guo Lixin, director of the Endocrinology Department of the National Geriatrics Center of Beijing Hospital, gave a wonderful interpretation.
Safety control, stratification of standards: the foundation of senile diabetes management In recent years, a large number of evidence-based medicine evidences have continuously emerged in the field of senile diabetes, and new hypoglycemic drugs have been continuously developed and marketed.
There is an urgent need for an authority based on the latest evidence-based medicine evidence and treatment concepts.
The guidelines are promulgated to effectively guide clinicians in the scientific and standardized management of elderly diabetic patients, increase the blood glucose compliance rate of the entire population of diabetic patients, and thereby achieve the goal of "Healthy China".After the top experts in the fields of endocrinology, cardiovascular, kidney disease, medical nutrition, etc.
brainstormed and discussed repeatedly, this China's first guideline for the diagnosis and treatment of senile diabetes was born.
The "Guide" refers to the latest research results in the field of senile diabetes at home and abroad, and covers 19 chapters such as senile diabetes epidemiology, diagnosis, blood glucose control goals, hypoglycemic treatment pathways, complication management, and comorbid diseases.
Taking into account the characteristics of elderly diabetic patients with many complications and/or associated diseases, high risk of hypoglycemia, and poor self-management ability of patients, it is scientific, time-sensitive and maneuverable, which is conducive to the scientific and standardized full-process management of elderly diabetes.
The "Guide" emphasizes that elderly diabetic patients have a high degree of heterogeneity, which requires comprehensive evaluation, and adopts hierarchical and individualized management strategies to reduce the risk of hypoglycemia, and proposes a "de-enhanced treatment strategy" suitable for elderly diabetic patients.
Professor Guo Lixin emphasized that safety control and stratification of standards are the "eight-character policy" for the standardized management of elderly diabetes.
Varies from person to person, tailored to your needs: The management of elderly diabetes is in our country.
There is a large population of elderly diabetes patients, but the diagnosis rate, treatment rate and compliance rate are low.
Moreover, such patients have atypical symptoms and often have complications and/or companions.
Onset: At the same time, the risk of hypoglycemia is high, and the ability to perceive hypoglycemia is poor.
In addition, there are multiple medications and cognitive impairments in the elderly with diabetes, which increase the difficulty of patients' self-management ability.
Therefore, the "Guide" recommends stratification according to the health status of elderly type 2 diabetes (T2DM) patients, that is, according to good, moderate and poor health status, different blood glucose control goals should be set, and patients should choose safe, simple, and accessible lowering The principle of sugar regimen and drug treatment includes: priority selection of drugs with lower risk of hypoglycemia; selection of simple and highly compliant drugs to reduce the risk of multiple drugs; weighing the risk-benefit ratio and avoiding overtreatment; paying attention to liver and kidney function and heart function , Complications and concomitant diseases.
Professor Guo Lixin pointed out that according to the efficacy and safety of the drugs, the "Guide" has made the first, second and third level recommendations for non-insulin hypoglycemic drugs.
This recommendation is not absolute and should be made flexibly based on clinical practice. For example, although sulfonylureas with a higher risk of hypoglycemia are recommended as the third level, they are also good drugs if used properly; dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium glucose cotransporter 2 (SGLT2) inhibition New-type hypoglycemic drugs such as drugs and glucagon-like peptide-1 (GLP-1) receptor agonists are not only effective, but also have low risk of hypoglycemia, and some can bring additional benefits, so they are recommended by the guidelines.
In addition to the GLP-1 receptor agonists dulaglutide and liraglutide can effectively reduce blood sugar, liraglutide also has evidence of secondary prevention of atherosclerotic cardiovascular disease (ASCVD), while dulaglutide With evidence of ASCVD primary prevention and secondary prevention, once a week, the operation is easier, and the patient's compliance is improved.
Professor Guo Lixin emphasized that the choice of hypoglycemic drugs should be based on the patient's health status, life expectancy, cardiovascular risk and other factors.
It varies from person to person, tailored to the individual, and is the way to manage diabetes in the elderly.
Multi-pronged approach and guardianship with peace of mind: the management of elderly diabetes requires that the risk of cardiovascular disease in diabetic patients is more than twice that of non-diabetic patients.
Age itself is a risk factor for ASCVD.
Therefore, ASCVD has also become a disability and disability for elderly diabetic patients.
An important cause of death.
The management of ASCVD and its risk factors in elderly diabetic patients is more worthy of attention.
Therefore, the "Guide" lists "aged diabetic atherosclerotic cardiovascular disease and risk factor management" as a separate chapter for a comprehensive elaboration.
"Professor Guo Lixin said that cardiovascular risk factors for elderly diabetic patients need a multi-pronged approach to comprehensive management, including smoking cessation, weight management, blood sugar, blood pressure and blood lipid management, and antiplatelet therapy.
In addition to the control of multiple cardiovascular risk factors, elderly diabetes The protection of patients’ heart and kidney target organs is also worthy of attention.
We have seen that a variety of new hypoglycemic drugs can not only effectively control sugar, but also bring heart and kidney benefits to elderly diabetic patients, such as the SGLT2 inhibitors and GLP mentioned above.
-1 receptor agonist. The REWIND study shows that dulaglutide has evidence of primary prevention in T2DM patients with high risk of ASCVD, and it can also obtain long-term cardiovascular protection when used in elderly diabetic patients with cardiovascular risk factors; in elderly patients with ASCVD In diabetic patients, dulaglutide also has evidence of secondary prevention.
At the same time, dulaglycotide also reduces the risk of non-fatal stroke, reduces cognitive impairment in patients with T2DM, and brings more benefits to elderly diabetic patients.
Taking a multi-pronged approach and guarding with peace of mind is the key to the management of diabetes in the elderly.
Summary As the first guideline for diagnosis and treatment of senile diabetes in China, the "Guidelines for Diagnosis and Treatment of Elderly Diabetes in China (2021 Edition)" combines the characteristics of elderly diabetic patients, and covers the epidemiology, diagnosis, blood sugar control goals, hypoglycemic treatment pathways, and complication management of senile diabetes The contents of 19 chapters including, comorbid diseases, etc.
have played a positive role in promoting the scientific and standardized management of elderly diabetes.
Safe control and stratification of standards are a new management concept brought by the "Guide" to elderly diabetic patients.
GLP-1 receptor agonists such as dulaglutide, which have hypoglycemic effects and cardiovascular benefits, can help realize this concept.
Obtained important recommendations in the "Guide".
Expert profileProfessor Guo Lixin, chief physician, professor, and doctoral supervisor, director of the Department of Endocrinology, National Center for Geriatrics, Beijing Hospital, director-designate of the Diabetes Branch of the Chinese Medical Association, vice chairman of the Endocrinology and Metabolism Branch of the Chinese Medical Association, standing director of the Beijing Medical Association, Beijing Medical Association Chairman of the Branch of Endocrinologists; Former Chairman of the Diabetes Branch of the Beijing Medical Association; Deputy Editor-in-Chief of Chinese Journal of Diabetes; Deputy Editor-in-Chief of Chinese Journal of Medical Frontiers Enjoy special allowance from the State Council
Maybe we can't fight the wrinkles that the years bring to our mothers, but for their health, we must work hard to spare! Today is Mother's Day.
While thanking mothers for their nurturing, we should pay more attention to the health of mothers.
As we grow up, our parents are getting older.
After they enter the old age, the risk of various chronic diseases gradually increases, and there is no lack of elderly diabetes, which has a significantly higher prevalence in my country.
Diabetes patients aged ≥65 years are defined as elderly diabetic patients, including elderly people diagnosed with diabetes before and after 65 years of age, and about half of them are female patients.
Data in 2019 shows that the number of elderly diabetic patients ≥ 65 years old in China is about 35.
5 million, ranking first in the world, accounting for a quarter of the global elderly diabetic patients, and showing an upward trend.
Clinically, elderly diabetic patients have their own characteristics, so how to carry out standardized management? On January 27, 2021, the "Guidelines for Diagnosis and Treatment of Diabetes in the Aged in China (2021 Edition)" (hereinafter referred to as "Guidelines") jointly organized and compiled by the National Geriatrics Center, Chinese Medical Association Branch of Geriatrics and China Geriatric Health Care Association (hereinafter referred to as "Guidelines") will be held in Beijing.
Convened.
What are the renewal of concepts brought about by the "Guide" in the management of elderly diabetes, and what recommendations have been made for clinical practice? To this end, Professor Guo Lixin, director of the Endocrinology Department of the National Geriatrics Center of Beijing Hospital, gave a wonderful interpretation.
Safety control, stratification of standards: the foundation of senile diabetes management In recent years, a large number of evidence-based medicine evidences have continuously emerged in the field of senile diabetes, and new hypoglycemic drugs have been continuously developed and marketed.
There is an urgent need for an authority based on the latest evidence-based medicine evidence and treatment concepts.
The guidelines are promulgated to effectively guide clinicians in the scientific and standardized management of elderly diabetic patients, increase the blood glucose compliance rate of the entire population of diabetic patients, and thereby achieve the goal of "Healthy China".After the top experts in the fields of endocrinology, cardiovascular, kidney disease, medical nutrition, etc.
brainstormed and discussed repeatedly, this China's first guideline for the diagnosis and treatment of senile diabetes was born.
The "Guide" refers to the latest research results in the field of senile diabetes at home and abroad, and covers 19 chapters such as senile diabetes epidemiology, diagnosis, blood glucose control goals, hypoglycemic treatment pathways, complication management, and comorbid diseases.
Taking into account the characteristics of elderly diabetic patients with many complications and/or associated diseases, high risk of hypoglycemia, and poor self-management ability of patients, it is scientific, time-sensitive and maneuverable, which is conducive to the scientific and standardized full-process management of elderly diabetes.
The "Guide" emphasizes that elderly diabetic patients have a high degree of heterogeneity, which requires comprehensive evaluation, and adopts hierarchical and individualized management strategies to reduce the risk of hypoglycemia, and proposes a "de-enhanced treatment strategy" suitable for elderly diabetic patients.
Professor Guo Lixin emphasized that safety control and stratification of standards are the "eight-character policy" for the standardized management of elderly diabetes.
Varies from person to person, tailored to your needs: The management of elderly diabetes is in our country.
There is a large population of elderly diabetes patients, but the diagnosis rate, treatment rate and compliance rate are low.
Moreover, such patients have atypical symptoms and often have complications and/or companions.
Onset: At the same time, the risk of hypoglycemia is high, and the ability to perceive hypoglycemia is poor.
In addition, there are multiple medications and cognitive impairments in the elderly with diabetes, which increase the difficulty of patients' self-management ability.
Therefore, the "Guide" recommends stratification according to the health status of elderly type 2 diabetes (T2DM) patients, that is, according to good, moderate and poor health status, different blood glucose control goals should be set, and patients should choose safe, simple, and accessible lowering The principle of sugar regimen and drug treatment includes: priority selection of drugs with lower risk of hypoglycemia; selection of simple and highly compliant drugs to reduce the risk of multiple drugs; weighing the risk-benefit ratio and avoiding overtreatment; paying attention to liver and kidney function and heart function , Complications and concomitant diseases.
Professor Guo Lixin pointed out that according to the efficacy and safety of the drugs, the "Guide" has made the first, second and third level recommendations for non-insulin hypoglycemic drugs.
This recommendation is not absolute and should be made flexibly based on clinical practice. For example, although sulfonylureas with a higher risk of hypoglycemia are recommended as the third level, they are also good drugs if used properly; dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium glucose cotransporter 2 (SGLT2) inhibition New-type hypoglycemic drugs such as drugs and glucagon-like peptide-1 (GLP-1) receptor agonists are not only effective, but also have low risk of hypoglycemia, and some can bring additional benefits, so they are recommended by the guidelines.
In addition to the GLP-1 receptor agonists dulaglutide and liraglutide can effectively reduce blood sugar, liraglutide also has evidence of secondary prevention of atherosclerotic cardiovascular disease (ASCVD), while dulaglutide With evidence of ASCVD primary prevention and secondary prevention, once a week, the operation is easier, and the patient's compliance is improved.
Professor Guo Lixin emphasized that the choice of hypoglycemic drugs should be based on the patient's health status, life expectancy, cardiovascular risk and other factors.
It varies from person to person, tailored to the individual, and is the way to manage diabetes in the elderly.
Multi-pronged approach and guardianship with peace of mind: the management of elderly diabetes requires that the risk of cardiovascular disease in diabetic patients is more than twice that of non-diabetic patients.
Age itself is a risk factor for ASCVD.
Therefore, ASCVD has also become a disability and disability for elderly diabetic patients.
An important cause of death.
The management of ASCVD and its risk factors in elderly diabetic patients is more worthy of attention.
Therefore, the "Guide" lists "aged diabetic atherosclerotic cardiovascular disease and risk factor management" as a separate chapter for a comprehensive elaboration.
"Professor Guo Lixin said that cardiovascular risk factors for elderly diabetic patients need a multi-pronged approach to comprehensive management, including smoking cessation, weight management, blood sugar, blood pressure and blood lipid management, and antiplatelet therapy.
In addition to the control of multiple cardiovascular risk factors, elderly diabetes The protection of patients’ heart and kidney target organs is also worthy of attention.
We have seen that a variety of new hypoglycemic drugs can not only effectively control sugar, but also bring heart and kidney benefits to elderly diabetic patients, such as the SGLT2 inhibitors and GLP mentioned above.
-1 receptor agonist. The REWIND study shows that dulaglutide has evidence of primary prevention in T2DM patients with high risk of ASCVD, and it can also obtain long-term cardiovascular protection when used in elderly diabetic patients with cardiovascular risk factors; in elderly patients with ASCVD In diabetic patients, dulaglutide also has evidence of secondary prevention.
At the same time, dulaglycotide also reduces the risk of non-fatal stroke, reduces cognitive impairment in patients with T2DM, and brings more benefits to elderly diabetic patients.
Taking a multi-pronged approach and guarding with peace of mind is the key to the management of diabetes in the elderly.
Summary As the first guideline for diagnosis and treatment of senile diabetes in China, the "Guidelines for Diagnosis and Treatment of Elderly Diabetes in China (2021 Edition)" combines the characteristics of elderly diabetic patients, and covers the epidemiology, diagnosis, blood sugar control goals, hypoglycemic treatment pathways, and complication management of senile diabetes The contents of 19 chapters including, comorbid diseases, etc.
have played a positive role in promoting the scientific and standardized management of elderly diabetes.
Safe control and stratification of standards are a new management concept brought by the "Guide" to elderly diabetic patients.
GLP-1 receptor agonists such as dulaglutide, which have hypoglycemic effects and cardiovascular benefits, can help realize this concept.
Obtained important recommendations in the "Guide".
Expert profileProfessor Guo Lixin, chief physician, professor, and doctoral supervisor, director of the Department of Endocrinology, National Center for Geriatrics, Beijing Hospital, director-designate of the Diabetes Branch of the Chinese Medical Association, vice chairman of the Endocrinology and Metabolism Branch of the Chinese Medical Association, standing director of the Beijing Medical Association, Beijing Medical Association Chairman of the Branch of Endocrinologists; Former Chairman of the Diabetes Branch of the Beijing Medical Association; Deputy Editor-in-Chief of Chinese Journal of Diabetes; Deputy Editor-in-Chief of Chinese Journal of Medical Frontiers Enjoy special allowance from the State Council
